You are here

AETC ShareSpot on DTG/3TC: First 2-Drug ART Regimen for Treatment Naive

Monday, April 22, 2019

TargetHIV

AETC Share Spot

The details on FDA's approval of DTG/3TC, the first two-drug antiretroviral regimen for treatment-naive patients, are outlined in the April 19 AETC ShareSpot, FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine. Authored by Susa Coffey, MD of the AETC NCRC, the article outlines the clinical trial basis for the regimen's approval and summarizes clinical recommendations on which patient should and should not be prescribed with this combination. 

Total views: 88